Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 166

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

Open access
Dai, Hanren, Zhang, Wenying, Li, Xiaolei, Han, Qingwang, Guo, Yelei, Zhang, Yajing, Wang, Yao, Wang, Chunmeng, Shi, Fengxia, Zhang, Yan, Chen, Meixia, Feng, Kaichao, Wang, Quanshun, Zhu, Hongli, Fu, Xiaobing, Li, Suxia, Han, Weidong·2015·OncoImmunology

Abstract

The engineering of T lymphocytes to express chimeric antigen receptors (CARs) aims to establish T cell-mediated tumor immunity rapidly. In this study, we conducted a pilot clinical trial of autologous or donor- derived T cells genetically modified to express a CAR targeting the B-cell antigen CD19 harboring 4-1BB and the CD3ζ moiety. All enrolled patients had relapsed or chemotherapy-refractory B-cell lineage acute lymphocytic leukemia (B-ALL). Of the nine patients, six had definite extramedullary involvement, and the rate of overall survival at 18 weeks was 56%. One of the two patients who received conditioning chemotherapy achieved a three-month durable complete response with partial regression of extramedullary lesions. Four of seven patients who did not receive conditioning chemotherapy achieved dramatic regression or a mixed response in the haematopoietic system and extramedullary tissues for two to nine months. Grade 2-3 graft-versus-host disease (GVHD) was observed in two patients who received substantial donor-derived anti-CD19 CART (chimeric antigen receptor-modified T) cells 3-4 weeks after cell infusions. These results show for the first time that donor-derived anti-CD19 CART cells can cause GVHD and regression of extramedullary B-ALL. This study is registered at www.clinicaltrials.gov as NCT01864889.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2015.1027469

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 166

Metadata

Authors
Dai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., Wang, Y., Wang, C., Shi, F., Zhang, Y., Chen, M., Feng, K., Wang, Q., Zhu, H., Fu, X., Li, S., & Han, W.
Venue
OncoImmunology
Published
2015-09-14
Volume
4
Issue
11
Pages
e1027469-e1027469
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W1881216623
Cited by
166
References
9
FWCI
8.71
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. https://app.cochat.ai/papers/10.1080/2162402x.2015.1027469
The paper
Dai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., Wang, Y., Wang, C., Shi, F., Zhang, Y., Chen, M., Feng, K., Wang, Q., Zhu, H., Fu, X., Li, S., & Han, W. (2015). Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. OncoImmunology. https://doi.org/10.1080/2162402x.2015.1027469

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.